Drug intelligence / Profile preview

JNJ-80948543

Development stage: Phase 1
Lead developer: Janssen Research & Development
Modality: Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

JNJ-80948543 is a fully human immunoglobulin G1 (IgG1) T-cell redirecting trispecific antibody developed for the treatment of B-cell malignancies such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia. It targets CD79b and CD20 antigens on tumor B-cells and the CD3 antigen on T-cells. By binding to these targets, it redirects and activates T-cells to recognize and kill malignant B-cells. The drug is being investigated in combination with other agents such as the bispecific antibody JNJ-75348780 in early-phase clinical trials[1][2][3][4][5][6][7].

Other names: anti-CD79b/CD20/CD3 trispecific antibody

Targets

B-cell antigen receptor complex-associated protein beta chainCD3 (T-cell surface glycoprotein CD3)CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on JNJ-80948543.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-80948543.

Explore the full profile